Abstract
Novel imidazoline derivatives were discovered to be potent neuropeptide Y Y5 receptor antagonists. High-throughput screening of Merck sample collections against the human Y5 receptor resulted in the identification of 2,4,4-triphenylimidazoline ( 1), which had an IC 50 of 54 nM. Subsequent optimization led to the identification of several potent derivatives.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have